000163725 001__ 163725
000163725 005__ 20230915090533.0
000163725 0247_ $$2pmid$$apmid:35453411
000163725 0247_ $$2doi$$a10.3390/antiox11040726
000163725 0247_ $$2altmetric$$aaltmetric:126108453
000163725 0247_ $$2pmc$$apmc:PMC9027925
000163725 037__ $$aDZNE-2022-00464
000163725 082__ $$a610
000163725 1001_ $$00000-0002-6660-948X$$aKaragianni, Korina$$b0
000163725 245__ $$aCarnosic Acid and Carnosol Display Antioxidant and Anti-Prion Properties in In Vitro and Cell-Free Models of Prion Diseases
000163725 260__ $$aBasel$$bMDPI$$c2022
000163725 3367_ $$2DRIVER$$aarticle
000163725 3367_ $$2DataCite$$aOutput Types/Journal article
000163725 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655121430_6958
000163725 3367_ $$2BibTeX$$aARTICLE
000163725 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163725 3367_ $$00$$2EndNote$$aJournal Article
000163725 520__ $$aPrion diseases are transmissible encephalopathies associated with the conversion of the physiological form of the prion protein (PrPC) to the disease-associated (PrPSc). Despite intense research, no therapeutic or prophylactic agent is available. The catechol-type diterpene Carnosic acid (CA) and its metabolite Carnosol (CS) from Rosmarinus officinalis have well-documented anti-oxidative and neuroprotective effects. Since oxidative stress plays an important role in the pathogenesis of prion diseases, we investigated the potential beneficial role of CA and CS in a cellular model of prion diseases (N2a22L cells) and in a cell-free prion amplification assay (RT-QuIC). The antioxidant effects of the compounds were confirmed when N2a22L were incubated with CA or CS. Furthermore, CA and CS reduced the accumulation of the disease-associated form of PrP, detected by Western Blotting, in N2a22L cells. This effect was validated in RT-QuIC assays, indicating that it is not associated with the antioxidant effects of CA and CS. Importantly, cell-free assays revealed that these natural products not only prevent the formation of PrP aggregates but can also disrupt already formed aggregates. Our results indicate that CA and CS have pleiotropic effects against prion diseases and could evolve into useful prophylactic and/or therapeutic agents against prion and other neurodegenerative diseases.
000163725 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163725 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000163725 7001_ $$00000-0002-9428-0159$$aPettas, Spyros$$b1
000163725 7001_ $$aKanata, Eirini$$b2
000163725 7001_ $$aLioulia, Elisavet$$b3
000163725 7001_ $$0P:(DE-2719)2811840$$aThune, Katrin$$b4$$udzne
000163725 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b5$$udzne
000163725 7001_ $$00000-0002-1439-3920$$aTsamesidis, Ioannis$$b6
000163725 7001_ $$aLymperaki, Evgenia$$b7
000163725 7001_ $$00000-0001-8759-8962$$aXanthopoulos, Konstantinos$$b8
000163725 7001_ $$aSklaviadis, Theodoros$$b9
000163725 7001_ $$00000-0003-4170-0612$$aDafou, Dimitra$$b10
000163725 773__ $$0PERI:(DE-600)2704216-9$$a10.3390/antiox11040726$$gVol. 11, no. 4, p. 726 -$$n4$$p726$$tAntioxidants$$v11$$x2076-3921$$y2022
000163725 8564_ $$uhttps://pub.dzne.de/record/163725/files/DZNE-2022-00464.pdf$$yOpenAccess
000163725 8564_ $$uhttps://pub.dzne.de/record/163725/files/DZNE-2022-00464.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163725 909CO $$ooai:pub.dzne.de:163725$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163725 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811840$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000163725 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163725 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163725 9141_ $$y2022
000163725 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163725 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-31
000163725 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTIOXIDANTS-BASEL : 2021$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-12T13:05:11Z
000163725 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-12T13:05:11Z
000163725 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-12T13:05:11Z
000163725 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-03-30
000163725 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANTIOXIDANTS-BASEL : 2021$$d2023-03-30
000163725 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x0
000163725 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x1
000163725 980__ $$ajournal
000163725 980__ $$aVDB
000163725 980__ $$aUNRESTRICTED
000163725 980__ $$aI:(DE-2719)1440011-1
000163725 980__ $$aI:(DE-2719)5000037
000163725 9801_ $$aFullTexts